文献速递骨软组织肉瘤与黑色素瘤

基于美国癌症联合委员会第8版验证的两个独立队列中I期和II期原发性黑色素瘤患者的预后:对辅助治疗的启示

Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment.
PubMed 文献 · J Clin Oncol · 2022-06-16

研究利用德国中枢恶性黑色素瘤登记处(CMMR)2000至2015年诊断的17,544例I期和II期原发性黑色素瘤患者,分为探索队列(6,725例)和验证队列(10,819例),比较其生存结局与已发表的AJCCv8 I期和II期生存数据。结果显示两个CMMR队列各分期的黑色素瘤特异性生存率均低于AJCCv8队列,IA-IIA期复发率约为黑色素瘤特异性死亡率的兩倍。

要点

  • CMMR队列10年黑色素瘤特异性生存率在IA期95.1%-95.6%、IB期89.7%-90.9%、IIA期80.7%-83.1%、IIB期72.0%-79.9%、IIC期57.6%-64.7%。
  • 对应AJCCv8队列10年黑色素瘤特异性生存率分别为IA期98%、IB期94%、IIA期88%、IIB期82%、IIC期75%。
  • IA-IIA期复发率约为黑色素瘤特异性死亡率的兩倍。

核心结论

  • 两个CMMR队列中各I期和II期患者的黑色素瘤特异性生存率均低于已发表的AJCCv8数据,这对该人群辅助治疗的考虑具有重要意义。

研究设计与样本

  • 德国中枢恶性黑色素瘤登记处(CMMR)评估了2000至2015年原发性诊断的I期和II期黑色素瘤患者17,544例。
  • 探索性队列由蒂宾根大学皮肤肿瘤中心6,725例患者组成;验证性队列由其他11个德国中心的10,819例患者组成。
  • 将生存结局与已发表的美国癌症联合委员会第8版(AJCCv8)I期和II期生存数据进行比较。

主要发现

  • 两个CMMR队列与AJCCv8队列相比,10年黑色素瘤特异性生存率在IA期为95.1%-95.6% vs 98%,IB期为89.7%-90.9% vs 94%,IIA期为80.7%-83.1% vs 88%,IIB期为72.0%-79.9% vs 82%,IIC期为57.6%-64.7% vs 75%。
  • 在IA-IIA期,复发率约为黑色素瘤特异性死亡率的兩倍。

关键数值与推荐

  • CMMR队列10年黑色素瘤特异性生存率:IA期95.1%-95.6%,IB期89.7%-90.9%,IIA期80.7%-83.1%,IIB期72.0%-79.9%,IIC期57.6%-64.7%。
  • AJCCv8队列10年黑色素瘤特异性生存率:IA期98%,IB期94%,IIA期88%,IIB期82%,IIC期75%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. PATIENTS AND METHODS: The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. RESULTS: For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. CONCLUSION: The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Garbe C, Keim U, Amaral T, et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. J Clin Oncol. 2022. PMID: 35709414. doi:10.1200/JCO.22.00202

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。